Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 16.89 0.66% 0.11
SNDX closed up 0.66 percent on Friday, June 5, 2020, on 65 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical SNDX trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Wide Bands Range Expansion 0.00%
Narrow Range Bar Range Contraction 0.66%
Inside Day Range Contraction 0.66%
Wide Bands Range Expansion 0.66%
Wide Bands Range Expansion 3.30%
Outside Day Range Expansion 0.78%
Wide Bands Range Expansion 0.78%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Cancer Therapies Pyridines Lung Cancer Late Stage Biopharmaceutical Hematological Malignancies Benzamides Carbamates Draft:Syndax National Cancer Institute

Is SNDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.97
52 Week Low 5.35
Average Volume 973,317
200-Day Moving Average 9.95
50-Day Moving Average 14.68
20-Day Moving Average 17.88
10-Day Moving Average 16.39
Average True Range 1.70
ADX 32.39
+DI 23.87
-DI 16.04
Chandelier Exit (Long, 3 ATRs ) 16.86
Chandelier Exit (Short, 3 ATRs ) 19.87
Upper Bollinger Band 21.26
Lower Bollinger Band 14.49
Percent B (%b) 0.35
BandWidth 37.85
MACD Line 0.28
MACD Signal Line 0.69
MACD Histogram -0.4138
Fundamentals Value
Market Cap 375.28 Million
Num Shares 22.2 Million
EPS -2.84
Price-to-Earnings (P/E) Ratio -5.95
Price-to-Sales 191.23
Price-to-Book 2.13
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.23
Resistance 3 (R3) 19.40 18.78 18.84
Resistance 2 (R2) 18.78 18.19 18.70 18.71
Resistance 1 (R1) 17.84 17.82 18.31 17.67 18.58
Pivot Point 17.22 17.22 17.46 17.14 17.22
Support 1 (S1) 16.28 16.63 16.75 16.11 15.20
Support 2 (S2) 15.66 16.26 15.58 15.07
Support 3 (S3) 14.72 15.66 14.94
Support 4 (S4) 14.55